China National Accord Medicines Corporation Ltd. (200028.SZ)
- Previous Close
12.12 - Open
12.15 - Bid 12.05 x --
- Ask 12.06 x --
- Day's Range
11.98 - 12.15 - 52 Week Range
10.15 - 16.19 - Volume
123,925 - Avg. Volume
142,193 - Market Cap (intraday)
14.298B - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
10.71 - EPS (TTM)
1.13 - Earnings Date --
- Forward Dividend & Yield 0.75 (6.17%)
- Ex-Dividend Date Jun 25, 2024
- 1y Target Est
--
China National Accord Medicines Corporation Ltd. engages in the retail and distribution of pharmaceutical products in China and internationally. It offers drugs, medical equipment, cargo transportation, warehousing, loading and unloading, glass instruments, cosmetics, sales of daily necessities, other business services, and other professional consulting services; agent services; and house leasing services. The company is also involved in the import and export of proprietary Chinese medicines, chemical preparations, antibiotics, biochemical drugs, biological preparations, diagnostic drugs, therapeutic and diagnostic biological products, packaged foods, chemical products, house supplies, and self-operated technologies. In addition, it engages in the retail and distribution of medical devices, as well as wholesale and retail of health supplies, etc. The company was formerly known as Shenzhen Health Mineral Water Corp., Ltd. The company was incorporated in 1993 and is headquartered in Shenzhen, China. China National Accord Medicines Corporation Ltd. operates as a subsidiary of Sinopharm Group Co., Ltd.
www.szaccord.com.cnRecent News: 200028.SZ
View MorePerformance Overview: 200028.SZ
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 200028.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 200028.SZ
View MoreValuation Measures
Market Cap
14.33B
Enterprise Value
14.79B
Trailing P/E
10.74
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.08
Price/Book (mrq)
0.35
Enterprise Value/Revenue
0.19
Enterprise Value/EBITDA
19.19
Financial Highlights
Profitability and Income Statement
Profit Margin
0.79%
Return on Assets (ttm)
1.75%
Return on Equity (ttm)
0.65%
Revenue (ttm)
73.58B
Net Income Avi to Common (ttm)
581.72M
Diluted EPS (ttm)
1.13
Balance Sheet and Cash Flow
Total Cash (mrq)
5.54B
Total Debt/Equity (mrq)
28.29%
Levered Free Cash Flow (ttm)
1.42B